Stock screener

RNA

Conviction 20HealthcareScan · Thu, Jun 25, 2026
RNA$12.80-0.23%
ResistanceSupportVol 14
63 bars
Vol MA14 239.01K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Atrium Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.aviditybiosciences.com
Price12.80
Change-0.23%
Gap+0.39%
Rel volume3.64×
Avg volume233.95K
Avg $ vol2.94M
SMA 2012.46
SMA 5012.95
SMA 20043.22
Price vs 50-1.17%
Price vs 200-70.38%
MA stackbearish
50/200 cross
Supertrenddown · 13.23
RSI (14)50
MACD hist0.15
MACD crossbull · 9d
Stoch %K / %D80 / 81
ADX (14)15
+DI / −DI21 / 14
RSI divergence
MACD divergence
ATR %+3.90%
ADR %4.17%
52w high72.93
52w low11.55
From 52w high-82.45%
Above 52w low+10.82%
New 52w highNo
SqueezeOff
Bollinger width15.13%
%B0.68
Donchian pos51.13%
Donchian high14.14
Donchian low11.40
AVWAP (52w high)47.59
vs AVWAP high-73.11%
AVWAP (52w low)12.66
vs AVWAP low+1.13%
OBV trendDown
Chaikin MF (20)-0.17
Today vs 20d3.64×
Avg vol (14d)239.01K
Avg vol (20d)233.95K
Avg $ vol (20d)2.94M
Market cap218.95M
RS 3m (vs SPY)-15.06%
RS 6m (vs SPY)-90.61%
RS line new highNo
Trend template0/8
Technical rank16.9
1 week+2.56%
1 month-1.99%
3 months-2.22%
6 months-82.31%
1 year-56.09%
YTD-82.25%
P/E
P/B0.94
P/S
P/FCF
EPS
Div yield
ROE
ROA
Debt/Eq
Current13.04
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth
Price target
Target upside
Analyst rating
Institutional
Ent. value-48.9M
Revenue19.64M
Net income-16.63M
Gross profit
Free cash flow
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out17.11M
Employees391
ListedFri, Feb 27, 2026
Free float16.24M
Float %94.9%
Short interest3.65M
Days to cover15.8d
Short volume44.7%
Squeeze score83 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction20 / 100
Pattern quality
Tech rank16.9 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance14.05
Support11.80
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RNA

All disclosures →
No recent disclosed trades by Congress in RNA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RNA · 10 buys

InsiderSideShares
Kenney Stephanie
See Remarks · Common Stock · 2026-04-20
Grant30K
Hughes Steven George
Chief Medical Officer · Stock Option (Right to Buy) · 2026-04-20
Grant60K
Kenney Stephanie
See Remarks · Stock Option (Right to Buy) · 2026-04-20
Grant60K
Hoyos Rocio Martin
Chief Strategy Officer · Common Stock · 2026-04-20
Grant30K
Winslow Brendan R.
Chief Financial Officer · Common Stock · 2026-04-20
Grant30K
Gallagher Kathleen P.
See Remarks · Stock Option (Right to Buy) · 2026-04-20
Grant205K
Hughes Steven George
Chief Medical Officer · Common Stock · 2026-04-20
Grant30K
Winslow Brendan R.
Chief Financial Officer · Stock Option (Right to Buy) · 2026-04-20
Grant60K
Gallagher Kathleen P.
See Remarks · Common Stock · 2026-04-20
Grant102.5K
Hoyos Rocio Martin
Chief Strategy Officer · Stock Option (Right to Buy) · 2026-04-20
Grant60K

SEC filings

EDGAR filings in RNA

EDGAR →

No recent SEC filings on file for RNA.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.